for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Boule Diagnostics AB

BOUL.ST

Latest Trade

78.80SEK

Change

5.10(+6.92%)

Volume

58,551

Today's Range

73.00

 - 

79.60

52 Week Range

37.45

 - 

79.60

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
73.70
Open
73.70
Volume
58,551
3M AVG Volume
0.36
Today's High
79.60
Today's Low
73.00
52 Week High
79.60
52 Week Low
37.45
Shares Out (MIL)
19.42
Market Cap (MIL)
1,530.02
Forward P/E
--
Dividend (Yield %)
0.76

Next Event

Q1 2020 Boule Diagnostics AB Earnings Release

Latest Developments

More

Boule Diagnostics Q4 Operating Profit Rises To SEK 15.1 Mln

Boule Diagnostics Names Christina Rubenhag Interim CEO

Boule Diagnostics Appoints Jesper Soderqvist CEO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Boule Diagnostics AB

Boule Diagnostics AB is a Sweden-based company engaged in the provision of medical diagnostic and testing equipment. The Company specializes in the development, manufacture and sale of complete blood count (CBC) systems in the field of hematology. It provides reagents, cleaning products and blood calibrators and controls that are used in human and veterinarian laboratories, as well as analyzers and complementing accessories for hematology systems. The Company’s product portfolio comprises five brands: Clinical Diagnostic Solutions, Exigo, Medonic, Swelab and Quintus. The Company’s primary customer base comprises small and medium-sized hospitals, clinics, diagnostics firms and laboratories. Furthermore, It operates worldwide through a number of subsidiaries, such as Boule Medical AB, Boule Nordic AB, Clinical Diagnostic Solutions Inc and Boule Medical (Beijing) Co Ltd.

Contact Info

Domnarsvgatan 4

+46.8.7447700

https://www.boule.com/

Executive Leadership

Peter von Ehrenheim

Independent Chairman of the Board

Christina Rubenhag

Acting President and Chief Executive Officer, Chief Financial Officer, Senior Vice President

Fredrik Dalborg

President, Chief Executive Officer

Fredrik Ekdahl

Senior Vice President Research & Development

Michael Elliott

Senior Vice President Research & Development at CDS

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, SEK)

2017

0.4K

2018

0.4K

2019

0.5K

2020(E)

0.5K
EPS (SEK)

2017

1.918

2018

2.110

2019

1.930

2020(E)

2.750
Price To Earnings (TTM)
40.71
Price To Sales (TTM)
3.07
Price To Book (MRQ)
4.60
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
46.08
LT Debt To Equity (MRQ)
18.20
Return on Investment (TTM)
10.03
Return on Equity (TTM)
6.89

Latest News

Latest News

BRIEF-Boule Diagnostics Q4 Operating Profit Rises To SEK 15.1 Mln

* Q4 NET SALES SEK 129.3 MILLION VERSUS SEK 106.2 MILLION YEAR AGO

BRIEF-Boule Diagnostics Appoints Jesper Soderqvist CEO

* JESPER SÖDERQVIST TAKES OFFICE MAY 11, 2020 AT THE LATEST Source text for Eikon:

BRIEF-Boule Diagnostics Receives Warning Letter From US FDA Authority

* SAID ON FRIDAY UNIT BOULE MEDICAL RECEIVED A WARNING LETTER FROM THE US FOOD AND DRUG ADMINISTRATION

BRIEF-Boule Diagnostics Unit Buys New Technologies From Drew Scientific

* UNIT BOULE MEDICAL AB BUYS NEW TECHNOLOGIES FROM DREW SCIENTIFIC, INC.

BRIEF-Boule Diagnostics Q4 Operating Profit Rises To SEK ‍14.9​ Million

* Q4 NET SALES SEK 107.2 MILLION VERSUS SEK 104.6 MILLION YEAR AGO

BRIEF-Boule Diagnostics Q3 operating profit grows to SEK ‍28.2​ mln

* Q3 NET SALES SEK 109.7 MILLION VERSUS SEK 108.5 MILLION YEAR AGO

BRIEF-Boule Diagnostics appoints ‍christina Rubenhag new CFO

* CHRISTINA RUBENHAG NEW CFO FROM OCT.9 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Boule Diagnostics Q2 net result swings to loss SEK 1.1 mln

* Q2 NET SALES SEK 104.3 MILLION VERSUS SEK 102.0 MILLION YEAR AGO

BRIEF-Boule Diagnostics closes factory in China

* BOULE DIAGNOSTICS OPTIMIZES MANUFACTURING STRUCTURE - CLOSES FACTORY IN CHINA

BRIEF-Boule Diagnostics Q1 operating profit rises to SEK 12.0 mln

* Q1 NET SALES SEK 106.6 MILLION VERSUS SEK 84.4 MILLION YEAR AGO

BRIEF-Boule Diagnostics wins strategic contract

* Installation of instruments will begin in Q2 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Boule Diagnostics Q4 operating profit grows to SEK 1.3 mln

* Q4 net sales 105.8 million Swedish crowns ($11.89 million) versus 88.4 million crowns year ago

BRIEF-Boule Diagnostics Q4 operating profit up at SEK 1.3 mln

* Q4 net sales 105.8 million Swedish crowns ($12 million)versus 88.4 million crowns year ago

BRIEF-Boule Diagnostics presents new targets, adjusts dividend policy

* Said on Wednesday had revised its financial targets and adjusted dividend policy

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up